Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | ADH1C | P00326 | 1/20 | 0.37 |
| ▸ | ADH1A | P07327 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20900599 | 1.00 | CYP1A2 (0.42) | CYP1A2ALOX5ADRA1BADH1CADH1A | |
| SCHEMBL12018411 | 1.00 | CYP1A2 (0.42) | CYP1A2ALOX5ADRA1BADH1CADH1A | |
| SCHEMBL8040461 | 0.97 | CYP1A2 (0.39) | CYP1A2ALOX5ADRA1BADH1CADH1A | |
| SCHEMBL26714515 | 0.95 | CYP1A2 (0.42) | CYP1A2ALOX5ADRA1BADH1CADH1A | |
| SCHEMBL9256109 | 0.92 | OPRM1 (0.41) | CYP1A2ALOX5ADRA1BADH1CADH1A | |
| SCHEMBL16577641 | 0.90 | CYP1A2 (0.39) | CYP1A2ALOX5ADRA1BADH1CADH1A | |
| SCHEMBL16577647 | 0.88 | CYP1A2 (0.38) | CYP1A2ALOX5ADRA1BADH1CADH1A | |
| SCHEMBL23482120 | 0.86 | OPRM1 (0.41) | CYP1A2ALOX5ADRA1BADH1CADH1A | |
| SCHEMBL24317286 | 0.86 | CYP1A2 (0.41) | CYP1A2ALOX5ADH1CADH1AACHE | |
| SCHEMBL26503755 | 0.86 | ALOX5 (0.39) | CYP1A2ALOX5ADRA1BADH1CADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114031974-A | Ink for ink jet printing and electroluminescent device | 广东聚华印刷显示技术有限公司 | 2022-02-11 | — | — | CN | claimed |
| US-20230322785-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | MERCK SHARP & DOHME LLC (US) | 2023-10-12 | — | — | US | disclosed |
| CN-114031974-B | Ink-jet printing ink and electroluminescent device | 广东聚华印刷显示技术有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-114031974-A | Ink for ink jet printing and electroluminescent device | 广东聚华印刷显示技术有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-10261043-B2 | Analyte sensor | PARKER-HANNIFIN CORPORATION (US) | 2019-04-16 | — | — | US | disclosed |
| US-20180066000-A1 | Metal Complexes and Electroluminescent Devices Comprising These Metal Complexes | MERCK PATENT GMBH (DE) | 2018-03-08 | — | — | US | disclosed |
| US-20170365786-A1 | COMPOSITIONS COMPRISING AT LEAST ONE POLYMER AND AT LEAST ONE METAL COMPLEX AND TO ELECTROLUMINESCENT DEVICES CONTAINING SAID COMPOSITIONS | MERCK PATENT GMBH (DE) | 2017-12-21 | — | — | US | disclosed |
| US-20170365785-A1 | COMPOSITIONS COMPRISING AT LEAST ONE POLYMER AND AT LEAST ONE SALT, AND ELECTROLUMINESCENT DEVICES CONTAINING SAID COMPOSITIONS | MERCK PATENT GMBH (DE) | 2017-12-21 | — | — | US | disclosed |
| US-9815940-B2 | Polymers containing substituted triarylamine units and electroluminescent devices containing said polymers | MERCK PATENT GMBH (DE) | 2017-11-14 | — | — | US | disclosed |
| US-20170146478-A1 | ANALYTE SENSOR | PARKER INTANGIBLES LLC | 2017-05-25 | — | — | US | disclosed |
| US-20150069303-A1 | POLYMERS CONTAINING SUBSTITUTED TRIARYLAMINE UNITS AND ELECTROLUMINESCENT DEVICES CONTAINING SAID POLYMERS | MERCK PATENT GMBH (DE) | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170146478-A1 | ANALYTE SENSOR | HAO2, PRDX1, MPO | CYP1A2 1912/4885ALOX5 1604/4885ADRA1B 4454/4885 |
| US-20230322785-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | ADORA2A, ADORA2B, ADORA1 | CYP1A2 1052/4885ALOX5 600/4885ADRA1B 26/4885 |
| US-20180066000-A1 | Metal Complexes and Electroluminescent Devices Comprising These Metal Complexes | OCIAD2, OCIAD1, ICOSLG | CYP1A2 1456/4885ALOX5 416/4885ADRA1B 1851/4885 |
| US-10261043-B2 | Analyte sensor | HAO2, PRDX1, MPO | CYP1A2 1912/4885ALOX5 1604/4885ADRA1B 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.